CGTLive®’s Weekly Rewind – December 5, 2025

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma

The agency's decision was based on results from an r/r MZL cohort in the phase 2 TRANSCEND FL clinical trial.

2. Key Unknowns Remain in Cell and Gene Therapy

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about how our understanding of advanced therapeutics is still evolving.

3. Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings

Developed by Regeneration Biomedical, the therapy leverages intracerebroventricular administration via an Ommaya reservoir to target ventricular stem cell niches.

4. Karlla W. Brigatti, MS, CGC, on Accelerating SMA Diagnosis and Treatment

The research director at the Clinic for Special Children discussed how screening at-risk patients can speed up diagnosis and treatment of spinal muscular atrophy.

5. ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal" With Anusha Kalbasi, MD

In episode 7 of ImmunoLogic, Kalbasi discussed his research on the use of IL-9 to enhance CAR-T efficacy.